This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
CareDx (CDNA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CareDx (CDNA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 2.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 3.03% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Surges 3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Icon PLC (ICLR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -62.50% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -250% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Acushnet Holdings, CareDx, Lululemon and Chewy highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Acushnet Holdings, CareDx, Lululemon and Chewy highlighted as Zacks Bull and Bear of the Day
Bear Of The Day:CareDX
by Brian Bolan
This stock has beaten the Zacks Consensus Estimate in each of the last four quarters but it has fallen to the lowest Zacks Rank.
CareDx (CDNA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 133.33% and 1.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CareDx (CDNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 120.00% and 9.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx (CDNA) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 1500.00% and 10.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: MACOM Tech, CrowdStrike, Zscaler, CareDx and Medifast
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MACOM Tech, CrowdStrike, Zscaler, CareDx and Medifast
Are You Looking for a Top Momentum Pick? Why CareDx (CDNA) is a Great Choice
by Zacks Equity Research
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Stocks With Unstoppable Growth to Buy in 2021
by Rajani Lohia
Investing in stocks which have outpaced the market in 2020, defying the impacts of the COVID-19 outbreak, and have the potential for greater returns in 2021 is advisable.
4 MedTech Stocks Up More Than 100% in 2020 With Room to Run
by Urmimala Biswas
We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.
CareDx's (CDNA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in CareDx (CDNA).
Zacks Industry Outlook Highlights: Apollo Medical, bioMerieux, CareDx and Harrow Health
by Zacks Equity Research
Zacks Industry Outlook Highlights: Apollo Medical, bioMerieux, CareDx and Harrow Health
4 Top Medical Services Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Service industry. AMEH, BMXMF, CDNA and HROW are well positioned to gain.
CareDx (CDNA) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
CareDx (CDNA) Is Up 12.28% in One Week: What You Should Know
by Zacks Equity Research
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.